Volunteer for NIAID-funded clinical studies related to smallpox on ClinicalTrials.gov.
Smallpox is a disfiguring and potentially deadly infectious disease caused by the Variola major virus. Before smallpox was eradicated, there were two forms of the disease worldwide: Variola major, the deadly disease, and Variola minor, a much milder form. According to some health experts, over the centuries smallpox was responsible for more deaths than all other infectious diseases combined.
The last naturally occurring case of smallpox was reported in 1977. In 1980, the World Health Organization declared that smallpox had been eradicated. Currently, there is no evidence of naturally occurring smallpox transmission anywhere in the world. Although a worldwide immunization program eradicated smallpox disease decades ago, small quantities of smallpox virus officially still exist in two research laboratories in Atlanta, Georgia, and in Russia.
Scientists have not studied variola virus well because of the hazards associated with potential exposure. In addition, by international agreement, smallpox may only be studied at the Centers for Disease Control and Prevention (CDC) high-containment facility or the high-containment facility in Russia. Experiments must be approved in advance by an international committee.
Vaccinia virus used to make a smallpox vaccine and closely related to variola, has been studied thoroughly. There is one major difference between the two viruses: vaccinia can infect several types of living beings, while variola infects only humans naturally and cynomolgus monkeys under highly artificial laboratory conditions.
Smallpox is highly contagious. In most cases, people get smallpox by inhaling droplets of saliva, which are full of virus, during face-to-face contact with an infected person. When someone becomes infected, they do not immediately feel sick or shed virus to their household contacts. Exposure to the virus is followed by an incubation period during which people do not have any symptoms and may feel fine. This incubation period averages about 12 to 14 days but can range from 7 to 17 days. During this time, people are not contagious. After the virus has multiplied and spread throughout the body, a rash and fever develop. This is the "illness" portion of the disease, and it is when someone is most infectious.
Some risk of transmission lasts until all scabs have fallen off. Contaminated clothing or bed linens also can spread the virus. Those caring for people with smallpox need to use special safety measures to ensure that all bedding and clothing from the infected person are cleaned appropriately with bleach and hot water. Caretakers can use disinfectants such as bleach and ammonia to clean contaminated surfaces.
The first symptoms of smallpox may be difficult to distinguish from other flu-like illnesses and include:
A characteristic rash, most prominent on the face, arms, and legs, follows 2 to 3 days after the first symptoms. The rash starts with flat red lesions (sores) that develop at the same rate. After a few days, the lesions become filled with pus. They begin to crust early in the second week. Scabs develop and then separate and fall off after about three weeks.
There is no proven treatment for smallpox. People with the disease can benefit from intravenous fluids and medicine to control fever or pain as well as antibiotics for any secondary bacterial infections that may occur. If an infected person gets the smallpox vaccine within 4 days after exposure to the virus, it may lessen the severity of illness or even prevent it. The majority of people with smallpox recover, but death may occur in up to 30 percent of cases. Those who do recover are often left with disfiguring scars.
To prevent the spread of smallpox, healthcare providers must
The currently licensed smallpox vaccine, which consists of a laboratory strain of vaccinia virus, is highly effective in preventing infection. Medical experts believe the vaccine may lessen the severity of, or even prevent, illness in unvaccinated people if given within 4 days of exposure to the virus.
The smallpox vaccine helps the body develop immunity to smallpox. The vaccine is made from a "pox"-type virus related to smallpox. The smallpox vaccine contains live vaccinia virus-unlike many other vaccines that use killed virus. The vaccine does not contain the smallpox virus and cannot transmit smallpox. Learn more about the smallpox vaccine from Centers for Disease Control and Prevention (CDC).
Few data exist showing just how long vaccinia vaccines protect people against smallpox infection. Therefore, those vaccinated against the smallpox virus before 1972 may be susceptible to the disease. Military and other high-risk groups (for example, scientists who work with vaccinia and other orthopoxviruses related to Variola major) have been getting the vaccine since the United States stopped routine smallpox vaccinations in 1972.
Healthcare providers do not use a hypodermic needle, usually used for vaccinations, to give the smallpox vaccine. Instead, they use a tiny, two-pronged needle that is dipped into the vaccine solution. When removed from the solution, the needle keeps a droplet of the vaccine. The needle is used to prick the skin, usually in the upper arm, a number of times within a few seconds. The pricking is not deep, but it will cause a sore spot and one or two droplets of blood.
If the vaccination is successful, a red and itchy bump develops at the vaccine site in 3 or 4 days.
People who get the vaccine for the first time have a stronger reaction than those who are revaccinated.
Most people experience normal, typically mild reactions to the vaccine, which go away without treatment. The vaccine often causes a low fever, swollen glands in the armpits, as well as skin redness at the vaccination site.
The vaccine, however, can cause several complications, some life-threatening, particularly in people with immune deficiencies and skin disorders. Based on reactions to smallpox vaccines in the past, the CDC estimates that between 14 and 52 out of every 1 million people vaccinated for the first time will have potentially life-threatening complications that require medical attention, including
CDC estimates 1 or 2 in 1 million people who receive the vaccine may die as a result of vaccination. Because of serious and potentially deadly reactions, health care providers must carefully screen potential vaccine recipients to ensure that those at increased risk do not receive the vaccine.
Healthcare providers treat certain serious complications with anti-vaccinia immune globulin-pooled antibodies taken from people recently immunized with the smallpox vaccine.
back to top
Last Updated October 22, 2014
Last Reviewed October 22, 2014